BioWa and Lonza announced that they have entered into research pharma deals with Pfizer allowing the use of the POTELLIGENT CHOK1SV Cell Line in the research and development of multiple proprietary antibodies in Pfizer’s pipeline.
POTELLIGENT CHOK1SV is a host cell line for manufacturing recombinant antibodies that combines the power of BioWa’s engineered glycosylation POTELLIGENT Technology with the advantages of Lonza’s industry leading GS Gene Expression System, which will be licensed to Pfizer as part of the pharma deals.
The GS System in question in the pharma deals includes Lonza’s pre-eminent host cell line, CHOK1SV.
The POTELLIGENT CHOK1SV Cell Line retains the desirable features of a high-producing cell line, with the advantage of a proven bioprocess platform for the CHOK1SV Cell Line.
Antibodies produced by this cell line, which will be part of the pharma deals, exhibit enhanced antibody dependent cellular cytotoxicity and can exert potent cytotoxic effects even when their target antigen is low.
In addition, they work in whole blood and retain all other desirable features of common antibodies.
Report: Partnering Deals and Alliances with Pfizer
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity